In large randomized trials of FDA-approved branded semaglutide, once-weekly treatment alongside lifestyle intervention produced substantial average weight loss over 68 weeks (Wilding et al., 2021), with continued treatment supporting weight maintenance (Rubino et al., 2021)
For EDS patients whose primary rationale for GLP-1 therapy is something other than diabetes MCAS management, joint pain reduction, or sleep apnea the coverage path is even less straightforward
In the same review, findings from a cross-sectional study with 1,575 cognitively healthy participants of the Framingham Study showed that individuals in the highest quartile of red blood cell DHA had significantly larger total brain volumes compared with those in the lowest quartile, independent of APOE genotype, homocysteine levels, and other vascular risk factor
improvements in blood pressure with meaningful systolic blood pressure reductions
Razor-sharp mental focus that lasts all day